指南一致性治疗与非子宫内膜样子宫内膜癌生存改善相关
基于美国国家癌症数据库2004–2014年非子宫内膜样子宫内膜癌女性,研究比较不同种族/民族接受指南一致性治疗(GCT)的差异及其与总生存的关系。结果显示43.8%接受了GCT,各族裔接受GCT的比值比无显著差异;GCT在非西班牙裔白人、非西班牙裔黑人和西班牙裔中与生存改善显著相关,在亚裔/太平洋岛民中不显著。
要点
- 非子宫内膜样子宫内膜癌中仅43.8%接受指南一致性治疗。
- 不同种族/民族间接受指南一致性治疗的比值比无显著差异。
- 指南一致性治疗在多数种族中与总生存改善相关,亚裔/太平洋岛民中不显著。
核心结论
- 超过半数非子宫内膜样子宫内膜癌女性未接受指南一致性治疗。
- 未观察到种族/民族间接受指南一致性治疗的显著差异。
- 接受指南一致性治疗在几乎全部种族中与生存改善相关。
研究设计与样本
- 基于美国国家癌症数据库的回顾性队列研究。
- 纳入2004–2014年诊断的非子宫内膜样子宫内膜癌女性:非西班牙裔白人21177例、非西班牙裔黑人6657例、西班牙裔1689例、亚裔/太平洋岛民903例。
- 依据年份特异性NCCN指南分类指南一致性治疗。
主要发现
- 总体43.8%的非子宫内膜样子宫内膜癌女性接受了指南一致性治疗。
- 与非西班牙裔白人相比,非西班牙裔黑人(OR=1.01,95%CI=0.95-1.07)、西班牙裔(OR=1.01,95%CI=0.91-1.12)和亚裔/太平洋岛民(OR=1.10,95%CI=0.96-1.26)接受指南一致性治疗的比值比无显著差异。
- 指南一致性治疗与非西班牙裔白人(HR=0.84,95%CI=0.80-0.87)、非西班牙裔黑人(HR=0.85,95%CI=0.80-0.91)和西班牙裔(HR=0.84,95%CI=0.72-0.98)的生存改善显著相关。
- 指南一致性治疗与亚裔/太平洋岛民的生存改善无显著相关(HR=0.97,95%CI=0.78-1.19)。
关键数值与推荐
- 指南一致性治疗依据年份特异性NCCN指南定义。
- 接受指南一致性治疗者占43.8%。
- 非西班牙裔白人HR=0.84(95%CI=0.80-0.87),非西班牙裔黑人HR=0.85(95%CI=0.80-0.91),西班牙裔HR=0.84(95%CI=0.72-0.98),亚裔/太平洋岛民HR=0.97(95%CI=0.78-1.19)。
临床怎么用
- 应关注提高非子宫内膜样子宫内膜癌患者对指南一致性治疗的依从性。
- 指南一致性治疗可能改善多数种族/民族患者的生存。
- 亚裔/太平洋岛民中指南一致性治疗的生存获益不显著,需进一步评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Among women diagnosed with non-endometrioid endometrial carcinoma (EC), we investigated associations between race/ethnicity and receipt of guideline-concordant treatment (GCT), as well as relationships between GCT and survival. METHODS: We used the National Cancer Database and identified 21,177 non-Hispanic White (NHW), 6657 non-Hispanic Black (NHB), 1689 Hispanic, and 903 Asian/Pacific Islander (AS/PI) women diagnosed with non-endometrioid EC between 2004 and 2014. Year-specific National Comprehensive Cancer Network (NCCN) guidelines were used to classify GCT. We used multivariable logistic regression to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for associations between race/ethnicity and GCT receipt. Multivariable-adjusted Cox proportional hazards models were used to estimate hazards ratios (HRs) and 95% CIs for relationships between GCT and overall survival in the total study population and stratified by race/ethnicity. RESULTS: Overall, 43.8% of women with non-endometrioid EC received GCT. Compared to NHW women, NHB (OR = 1.01, 95% CI = 0.95-1.07), Hispanic (OR = 1.01, 95% CI = 0.91-1.12) and AS/PI women (OR = 1.10, 95% CI = 0.96-1.26) did not have significantly different odds of receiving GCT. GCT was significantly associated with improved survival among NHW (HR = 0.84, 95% CI = 0.80-0.87), NHB (HR = 0.85, 95% CI = 0.80-0.91), and Hispanic women (HR = 0.84, 95% CI = 0.72-0.98) but not among AS/PI women (HR = 0.97, 95% CI = 0.78-1.19). CONCLUSIONS: While more than half of women with non-endometrioid EC did not receive GCT, no difference in GCT receipt by race/ethnicity was observed. When received, GCT was associated with improved survival in almost all racial groups. Interventions to improve GCT adherence may improve survival for most women with non-endometrioid EC.
引用
- Dholakia J, Llamocca E, Quick A, et al. Guideline-concordant treatment is associated with improved survival among women with non-endometrioid endometrial cancer. Gynecol Oncol. 2020. PMID: 32217002. doi:10.1016/j.ygyno.2020.03.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。